Q-omics provides the consensus-scored TMC2 profile across patient tissues and cancer cell-line models. TMC2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMC2 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, TMC2 RNA expression shows 18,104 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LUAD, and UVM as cancer lineages where TMC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMC2 survival associations across molecular data types. TMC2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMC2 RNA expression–survival associations across cancer types. High TMC2 expression shows unfavorable associations in KIRC, COAD and LIHC, but favorable associations in MESO, PAAD and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMC2 RNA expression.
This table summarizes TMC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for TMC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMC2 shows lower tumor expression in LUAD, LUSC, BRCA and UCEC and higher tumor expression in LIHC and CHOL. The LUAD box plot shows higher TMC2 RNA expression in normal versus tumor tissue (log2 FC = −0.649, t-test p < 0.001).
This table shows molecular features associated with TMC2 in patient tissues and cancer cell lines. In patient samples, TMC2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
